Latest offer to WellNow is lower than a decade ago SYRACUSE, N.Y., Dec. 29, 2023 /PRNewswire/ — The latest offer from Excellus BlueCross BlueShield to Upstate New York’s largest urgent care services provider is less than it paid ten years ago while over the same time period has convinced New York State to raise its prices … Read more
DUBLIN, Dec. 29, 2023 /PRNewswire/ — The “Global Analytical Standards Market by Category (Organic, Inorganic), Technique (GC, MS, LC, IR, NMR, Gravimetry), Method (Bioanalytical, Dissolution, Material Testing), Application (Food, Environmental, Pharmaceutical, Forensics) and Region – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. The global analytical standards market is projected to reach USD … Read more
BOULDER, Colo., Dec. 28, 2023 /PRNewswire/ — Dr. Larry Gold, the founder of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic’s current Chief Technology Officer, are issuing the below letter to SomaLogic’s stockholders regarding their opposition to the Company’s proposed merger with Standard BioTools, Inc. (“Standard”) (Nasdaq: LAB). Dear Fellow … Read more
– Approximately 3% of all outstanding shares…The scheduled date is Dec 29th SEOUL, South Korea, Dec. 27, 2023 /PRNewswire/ — Hugel, a global total medical aesthetics company, announced that it has held a board of directors meeting on the 22nd and passed a resolution to retire 371,563 shares of its own stock to enhance the … Read more
FORT LAUDERDALE, Fla., Dec. 27, 2023 /PRNewswire/ — The Law Offices of Jason Turchin is proud to announce the expansion of its National Product Liability division, now extensively covering a multitude of sectors affected by defective products. This expansion is a testament to the firm’s commitment to consumer safety and accountability in manufacturing. Consumer ProductsOur enhanced … Read more
TAIPEI and SAN DIEGO, Dec. 26, 2023 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that Taiwan Food and Drug Administration has approved its Phase II IND application of Silmitasertib (CX-4945) to treat patients with community-acquired pneumonia (CAP) caused … Read more
La création de ce centre démontre l’engagement de l’entreprise à fournir des solutions adaptées aux défis de la gynécologie et de la pédiatrie SHANGHAI, 25 décembre 2023 /PRNewswire/ — Changchun GeneScience Pharmaceutical (« GenSci »), une filiale de Changchun High-Tech Industries (Group), a organisé le 15 décembre une cérémonie de pose de la première pierre de son nouveau … Read more
DENVER, Dec. 24, 2023 /PRNewswire/ — As the holiday season brings joy and festivities, it also comes with its share of health concerns for many community members. Traditionally, emergency rooms (ER) have been the go-to destination for holiday health mishaps; however, DispatchHealth offers another option for urgent medical care—one that delivers healthcare right to patients’ … Read more
Encuesta de Heluna Health identifica una serie de deficiencias en el conocimiento y las barreras socio económicas que dificultan la preparación ante brotes epidémicos LOS ÁNGELES, 23 de diciembre de 2023 /PRNewswire-HISPANIC PR WIRE/ — Una quinta parte de los adultos estadounidenses afirma que no estarían en condiciones de aislar a un miembro enfermo de … Read more
The Establishment of the Facility Demonstrates the Company’s Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ — Changchun GeneScience Pharmaceutical (“GenSci”), a subsidiary of Changchun High-Tech Industries (Group), held a groundbreaking ceremony for its new global headquarters and research & development (R&D) center at Shanghai Zhangjiang International Medical … Read more